For those living with the most relentless form of multiple sclerosis, medicine has long offered little more than the counsel of endurance. A major international trial published in The Lancet this week suggests that ocrelizumab — already used in earlier-stage disease — can meaningfully slow the advance of disability even in patients once considered beyond the reach of treatment, reducing progression risk by 30 percent and preserving the hand function that patients themselves identified as their most precious remaining independence. The ORATORIO-HAND study, spanning 22 countries and more than 1,
News-Medical
· May 29, 2026
· health
· 3 min de lectura
High
Verificación: Verificado
Ocrelizumab shown to slow disability in advanced MS, including wheelchair users
The study demonstrates potential to reduce wheelchair dependency and preserve independence for advanced MS patients, improving quality of life for those with progressive disability.
◉
Health & Medicine
8293 artículos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% coincidencia
US Narrows Childhood Vaccine Schedule; Doctors Warn of Public Health R…
Times Now · 99% coincidencia
Next-gen KRAS inhibitor elisrasib shows stronger response rates than f…
Medical Xpress · 99% coincidencia
BioNTech, OncoC4 Report 54% Death Risk Reduction for Lung Cancer Drug …
The Manila Times · 99% coincidencia
mRNA COVID Vaccines Show Survival Boost in Advanced Cancer Patients
Devdiscourse · 99% coincidencia
Cobertura Relacionada
7NEWS · Aug 23
Model's Foot Cut Led to Heart Surgery, Baby Loss—Now Advocating for Better Diagnostics
Australian model Leah Ramsey lost her baby after a small foot cut triggered a rare heart infection that was repeatedly m…
Informanté · Aug 23 South Africa Shares FMD Vaccines as Region Strengthens Disease ControlsSouth Africa reports its largest-ever FMD outbreak is coming under control through accelerated vaccination and regional …
Al Jazeera · Aug 23 Solar telemedicine kiosks expand healthcare access across rural ChadSolar-powered telemedicine kiosks in rural Chad enable remote doctor consultations at a fraction of traditional travel c…
Inquirer.net · Aug 23 Prince Harry returns to UK amid family rifts, seeking reconciliation with monarchyPrince Harry and Meghan Markle are relocating back to Britain after six years in California, potentially signaling recon…
Sesgo y Encuadre
⚖
Medical news article presents clinical trial results with positive framing toward ocrelizumab efficacy; minimal bias detected in factual reporting of study outcomes.
Bias Direction
center
Confidence
MED
Positive outcome framing emphasizing clinical benefits and study significance; uses percentages to highlight treatment advantages; frames study design as addressing previous research gaps.
significantly slows disability progression
goes a long way to settle that debate
largest placebo-controlled treatment trial to date
major international phase III clinical trial
Patient experiences or testimonials
Cost/accessibility considerations for the medication
Adverse effects or safety concerns beyond efficacy data
Perspective from patients who did not benefit
Comparison to alternative treatment approaches
Long-term follow-up data or durability of effects
Impacto Geopolítico
🌎
Medical breakthrough in MS treatment has no direct geopolitical implications; this is a healthcare advancement with potential global health equity considerations.
Escalation Risk
low
Confidence
HIGH
Lente Económico
📈
Ocrelizumab trial demonstrates 30% reduction in disability progression for advanced MS patients, potentially expanding treatment market and improving outcomes for previously undertreated populations.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical/Biotechnology
Healthcare Services
Medical Devices
Health Insurance
Long-term Care Facilities
MS patients, particularly those with advanced disease and wheelchair users, gain access to effective treatment reducing disability progression and wheelchair dependency. Improved quality of life may reduce long-term care costs for households and caregivers, though drug costs may be substantial.
Regulatory approval expansion likely for ocrelizumab in advanced PPMS populations. Healthcare systems may need to revise treatment guidelines and reimbursement policies to include advanced-stage patients previously excluded. Potential cost-benefit analyses required by payers given treatment efficacy in broader populations.